FY2025 Earnings Forecast for iBio Issued By Chardan Capital

iBio, Inc. (NYSE:IBIO) – Equities research analysts at Chardan Capital issued their FY2025 earnings per share estimates for shares of iBio in a report issued on Monday, March 24th. Chardan Capital analyst K. Nakae expects that the company will post earnings of ($1.53) per share for the year. The consensus estimate for iBio’s current full-year earnings is ($1.74) per share.

Separately, StockNews.com raised iBio to a “sell” rating in a report on Tuesday, March 18th.

iBio Stock Up 2.3 %

Shares of NYSE IBIO opened at $4.41 on Thursday. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.05. The business has a fifty day simple moving average of $4.10 and a two-hundred day simple moving average of $3.03. iBio has a twelve month low of $1.50 and a twelve month high of $6.89.

Insider Activity at iBio

In other news, Director David Arkowitz bought 18,382 shares of iBio stock in a transaction on Friday, January 10th. The shares were bought at an average cost of $2.72 per share, with a total value of $49,999.04. Following the completion of the purchase, the director now directly owns 18,382 shares of the company’s stock, valued at approximately $49,999.04. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.58% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On iBio

A hedge fund recently raised its stake in iBio stock. Geode Capital Management LLC raised its stake in iBio, Inc. (NYSE:IBIO) by 52.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 83,797 shares of the company’s stock after purchasing an additional 28,775 shares during the period. Geode Capital Management LLC owned 0.85% of iBio worth $205,000 as of its most recent SEC filing. 7.90% of the stock is currently owned by hedge funds and other institutional investors.

iBio Company Profile

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.